Myoadenylate deaminase deficiency …

Richard L Sabina PhD

Neuromuscular Disorders

Updated 02.22.2024
Released 10.03.1994
Expires For CME 02.22.2027

Myoadenylate deaminase deficiency

Author: Richard L Sabina PhD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Myoadenylate deaminase deficiency

In This Article

Quick Link

Introduction

Overview

The author describes the genetic and clinical features of myoadenylate deaminase (mAMPD) deficiency, one of the most common metabolic disorders in the Caucasian population. Although a small percentage of mAMPD-deficient individuals present with exercise-induced cramping and pain, most are asymptomatic. However, genetic and physiological studies show that asymptomatic control subjects display functional abnormalities during aerobic exercise and that the mAMPD-deficient genotype is underrepresented in various groups of elite athletes. Lower anaerobic performance is also observed in elite athletes who participate in sprint/power-oriented sports and carry a mutant mAMPD allele compared to those elite athletes who have two normal mAMPD alleles. In addition, genotype-phenotype correlations indicate that asymptomatic individuals may also be at risk for developing a myopathy triggered by lipid-lowering drug therapy. Harboring one or more mutant alleles may reduce one's ability to achieve elite athletic status due in part to lower individual muscle strength, and also raises the risk of sports injury. Other correlative studies suggest that an inherited AMPD1 mutation has potential prognostic value for survival, obesity, hyperglycemia, and diabetes in specific subgroups of patients with heart disease; for response to methotrexate treatment in rheumatoid arthritis and juvenile idiopathic arthritis; and for side effects from regadenoson used in myocardial perfusion imaging.

Key points

	• Myoadenylate deaminase deficiency is an autosomal recessive disorder of skeletal muscle purine metabolism and is most commonly found in Caucasians.
	• Although rare alleles have been identified in all examined populations, a prevalent AMPD1 nonsense mutation accounts for the approximate 2% incidence of myoadenylate deaminase deficiency in Caucasians.
	• Although most individuals with an inherited myoadenylate deaminase deficiency are asymptomatic, physiological studies reveal measurable deficits in performance, lower leg muscle strength, and cardiorespiratory response to exercise.
	• Exertional myalgia is the most common clinical presentation in symptomatic myoadenylate deaminase deficiency, suggesting a contribution of other causative factors in this patient cohort.
	• Coincidental inheritance of one or more myoadenylate deaminase mutant alleles can be synergistic in other inherited disorders of skeletal muscle energy metabolism.
	• Correlative studies suggest that an inherited AMPD1 mutation has potential prognostic value in specific subgroups of patients with heart disease, for methotrexate treatment in patients with rheumatoid arthritis, and as a genetic determinant of athletic performance and status, and risk of side effects from regadenoson, an adenosine analogue currently used in myocardial perfusion imaging.

Historical note and terminology

Myoadenylate deaminase (muscle AMP deaminase) deficiency was first described as a "new disease of muscle" by Fishbein and colleagues in 1978 (16). Five young males, in a series of 250 biopsies, presented with the "chief complaint (often since childhood) of muscle weakness or cramping after exercise. Physical and neurologic examinations were normal except for decreased muscle mass, hypotonia, and weakness in some cases" (16). A relatively noninvasive and simple blood test was also described that is used to initially evaluate suspected cases. This diagnostic test is based on the lack of exertional increase in plasma ammonia in patients, and it exploits the fact that AMP deaminase represents the major ammonia-producing enzymatic activity in muscle. This characteristic had facilitated identification of the enzyme many years earlier.

However, earlier reports had described muscle AMP deaminase deficiency in some patients who had other neuromuscular disorders such as hypokalemic periodic paralysis, Duchenne muscular dystrophy, and inflammatory myopathy (10; 28). The most severe among these patients typically showed not only AMP deaminase deficiency but also decreased values of muscle creatine kinase activity and noncollagen protein (28). Kar and Pearson wrote that "undoubtedly these changes are secondary to the major pathologic alterations that have affected these muscles from a multiplicity of causes." Furthermore, "unlike creatine kinase, AMP deaminase appears to be more sensitive to degeneration of muscle caused by certain diseases." Fishbein, whose patients exhibited normal muscle creatine kinase activities, wrote that "the relation of (these earlier cases) to our series is obscure" (16).

Numerous reports of myoadenylate deaminase deficiency soon followed, approximately half of which were associated with other neuromuscular complications. An inability to ascribe a single clinical picture to myoadenylate deaminase deficiency prompted one group of investigators to proclaim myoadenylate deaminase deficiency as simply "a normal variant rather than a disease state" (63). This viewpoint was subsequently supported by others (25).

In order to explain the clinical heterogeneity, in 1985 Fishbein subdivided myoadenylate deaminase into inherited and acquired forms based on a variety of biochemical and immunological criteria (14). Inherited myoadenylate deaminase deficiency included cases with exertional myalgia but without other known neurologic, pathologic, or biochemical abnormalities. Acquired myoadenylate deaminase deficiency included cases secondary to other neuromuscular disorders. In comparing numerous cases classified according to these criteria, Fishbein showed that muscle biopsies from patients with acquired myoadenylate deaminase deficiency had generally higher residual enzyme activities; these were also more immunoreactive with anti-myoadenylate deaminase antibodies. Consistent with the earlier report by Kar and Pearson, Fishbein also observed in these biopsies less severe decreases of other enzymatic activities (eg, muscle creatine and adenylate kinases). He presumed that these nonspecific changes in muscle enzymatic activities reflected "generalized muscle damage." Careful review of biochemical data from all reported cases support Fishbein's distinction of inherited and acquired forms of myoadenylate deaminase deficiency; however, overlap between the two groups precludes classification based on any one of these criteria alone (55).

Fishbein also suggested that inherited myoadenylate deaminase deficiency was "a complete gene block (transmitted) in an autosomal recessive pattern" (14). Based on the high frequency of the inherited condition (2%), he concluded that "the heterozygous state is common." To explain the apparent vulnerability of AMP deaminase to other muscle pathologies in the acquired forms of myoadenylate deaminase deficiency, Fishbein proposed that "these patients might have been carriers (of the inherited deficiency), whose adenylate deaminase levels have been lowered to the deficient category by the advent of other neuromuscular disease."

Beginning in the late 1980s, efforts to delineate the molecular biology of AMP deaminase expression provided critical evidence in support of Fishbein's hypotheses regarding inherited and acquired forms of myoadenylate deaminase deficiency: the myoadenylate deaminase gene, AMPD1, is located on the short arm of chromosome 1 (58). Different molecular profiles are evident in cases classified as inherited or acquired myoadenylate deaminase deficiency (56). A single mutant AMPD1 allele is responsible for most cases of inherited deficiency (37) and for a subset of acquired deficiency with a coincidental inherited deficiency (71). Subsequently, additional rare mutant alleles have been identified across several ethnic groups (23; 68; 12; 61).

The estimated frequency of the common mutant AMPD1 allele is 11% to 14% in the Caucasian population (37; 22; 41; 47). These incidences not only account for nearly all symptomatic cases of inherited myoadenylate deaminase deficiency but also indicate that 2% of the Caucasian population is homozygous for the common mutant allele. Because 2% of this entire population does not exhibit myopathic symptoms, this identifies a relatively large group of asymptomatic, inherited myoadenylate deaminase deficient individuals. These data also suggest that additional determinants are involved in the clinical manifestations associated with an inherited myoadenylate deaminase deficiency.

Clinical manifestations

Presentation and course

Exertional myalgia is the predominant clinical symptom in 93% of reported cases of inherited symptomatic myoadenylate deaminase deficiency (55). The median age at the time of diagnosis is 37 years, with a range from 14 to 76 years. In 79% of patients, onset of symptoms occurs between childhood and the early adult years. In these patients, the disease does not appear to be progressive. In patients with acquired myoadenylate deaminase deficiency, clinical manifestations appear to be dictated by the associated neuromuscular disease and are, therefore, heterogeneous. Prognosis in these patients seems unrelated to their myoadenylate deaminase deficiency, again being related to the associated neuromuscular disorder. However, synergistic effects may be observed in patients with a coincidental inherited deficiency and an associated metabolic disorder (69; 49; 03). Finally, based on the relatively high frequency of the mutant AMPD1 allele in Caucasians, many asymptomatic individuals with inherited myoadenylate deaminase deficiency exist in this population. Individuals with inherited asymptomatic myoadenylate deaminase deficiency may, however, be at risk of developing exertional myalgia.

Although inherited symptomatic myoadenylate deaminase deficiency typically causes only exertional myalgia, other manifestations may occur (57; 43). Myoglobinuria following strenuous exercise has been reported in three patients. Increased serum creatine kinase has been found in 48%. In many patients, however, serum creatine kinase activity was normal at rest and increased into the abnormal range only following exercise. EMG findings may be normal, but minor abnormalities have been described in some patients. Results of muscle biopsy examined by routine histochemical stains and electron microscopy have varied from no pathologic findings to mild abnormalities in distribution of fiber size.

Clinical trials employing patients with inherited symptomatic myoadenylate deaminase deficiency and age- and sex-matched controls indicate that the relative intensity of exertion may dictate dysfunctional manifestations of this disorder. For example, exercise performance is significantly reduced in affected individuals performing moderate-intensity bicycle ergometer testing to fatigue (60) and submaximal isometric contractions (08). Conversely, no differences in performance are observed in ischemic isometric exercise (64) or maximal short-term electrically induced activation (09). One study conducted with asymptomatic subjects indicates similar sprint exercise performances across AMPD1 genotypes (44). However, others have shown that asymptomatic deficient subjects have diminished exercise capacity and cardiorespiratory responses in the sedentary state, limited training response during maximal exercise (47), and faster power decrease, reduced power output, and altered blood flow response during a 30-s Wingate cycling test (12; 42). Although a reduction of peak oxygen consumption is moderate in symptomatic subjects, their greater oxygen cost (ΔV’O2/ΔWork-Rate) slope may reduce exercise tolerance by increasing perceived effort (45). Although there is no evidence for diminished aerobic exercise capacity with the heterozygous genotype (47; 51), augmented hyperemia (24; 48) and decreased tissue damage (48) have been reported in response to forearm ischemia in these individuals compared to normal homozygotes. Moreover, a study of unrelated Caucasian patients with coronary artery disease observed a significantly lower relative increase in peak VO2 after 3 months of training in a cohort comprised of heterozygotes and homozygotes for the common mutant AMPD1 allele compared to individuals homozygous for the normal allele (66).

Prognosis and complications

Inherited symptomatic myoadenylate deaminase deficiency has no consistent complications other than exertional myalgia. Although inherited symptomatic myoadenylate deaminase deficiency is typically associated with exertional myalgia, the reverse is not true; exertional myalgia does not imply inherited myoadenylate deaminase deficiency. Many patients presenting with this relatively common clinical complaint have normal skeletal muscle AMP deaminase activity (36).

Conversely, patients with acquired and coincidental inherited myoadenylate deaminase deficiencies have a wide array of complications that are characteristic of the various associated primary neuromuscular diseases. For example, acquired myoadenylate deaminase deficiency may appear as a secondary phenomenon in advanced stages of many neuromuscular diseases (28), although it is not found in all cases of advanced-stage neuromuscular disease due to the proposed contribution of the mutant AMPD1 allele in the acquired condition (14). Coincidental inherited deficiency may also present with more severe clinical complications when associated with another metabolic defect.

Clinical vignette

Although onset of exertional myalgia may occur at any time during the teenage to middle years, the following case report illustrates a typical example of inherited symptomatic myoadenylate deaminase deficiency.

A 20-year-old woman developed increasing difficulty with muscle fatigue on heavy exercise. This had previously not been a problem, and she had participated in varsity-level tennis and basketball at college. The neurologic exam was entirely normal, creatine kinase was normal repeatedly, and muscle biopsy revealed normal histochemistry with the exception of the absent AMPDA. The patient's mother had no specific complaints referable to muscle, and her muscle biopsy was normal (63).

Genetic testing will also be included in more case studies to confirm a compete AMPD1 deficiency, either homozygous for the common mutant allele or, less frequently, a compound heterozygote with a minor variant.

Biological basis

Etiology and pathogenesis

Myoadenylate deaminase produces ammonia (NH3) and inosine monophosphate (IMP) from adenosine monophosphate (AMP). This enzyme reaction is a component of the purine nucleotide cycle (PNC), which is thought to play an important role in skeletal muscle function for several reasons (31). Activities of the three PNC enzymes, including adenylosuccinate synthetase and adenylosuccinate lyase that re-synthesize AMP from IMP, are several-fold greater in skeletal muscle than in other tissues, and myoadenylate deaminase activity is approximately 100 times greater than that of the other two enzymes. During exercise, NH3 production and IMP content of skeletal muscle increase in proportion to the work performed by the muscle, indicating increased myoadenylate deaminase activity under these conditions. Activation of myoadenylate deaminase and increased flux through the PNC during exercise lead to an increase in energy production through the generation of intermediates for the citric acid cycle from amino acids and through stimulation of glycolysis. Thus, one might anticipate that deficiency of myoadenylate deaminase activity and disruption of the PNC would lead to skeletal muscle dysfunction.

Most individuals with inherited myoadenylate deaminase deficiency are homozygous for a single mutant allele of the AMPD1 gene, which includes a C->T transition at nucleotide +34. This creates a nonsense codon, Q12X, in the myoadenylate deaminase mRNA that would be predicted to produce a severely truncated polypeptide devoid of enzymatic activity. Acquired myoadenylate deaminase deficiency is recognized in patients exhibiting advanced stages of other neuromuscular disorders who are also carriers of an AMPD1 mutant allele. In these individuals, pathologic change associated with unrelated neuromuscular disorders lowers AMP deaminase activities into the deficient range. This scenario has been documented in two unrelated cases of myotonic dystrophy and a single case of Sjögren syndrome (54) and described in an acquired myoadenylate deaminase deficiency with Type II muscle fiber atrophy (34); it also has been referred to in a number of other cases with severe neuromuscular disease (15). However, a coincidental inheritance of the homozygous mutant genotype has been reported in 10 individuals with a variety of other neuromuscular disorders (71). A coincidental inheritance of myoadenylate deaminase deficiency has also been documented in six patients with inherited defects in either the myophosphorylase (69; 49; 50; 35) or phosphofructokinase (03) genes. Notably, five of these six subjects exhibited clinical features that were more severe than expected for either condition alone. The emergence of coexisting, multiple neuromuscular disorders in patients exhibiting complex phenotypes has been editorialized with special reference to myoadenylate deaminase deficiency (72). In addition, individuals have been identified who present with clinical symptoms consistent with abnormal energy metabolism due to partial defects in multiple pathways, including myoadenylate deaminase, a condition termed “synergistic heterozygosity” (74). Finally, heterozygosity at the AMPD1 locus may contribute to the clinical variability of other inherited disorders, such as reduced submaximal aerobic capacity in females with McArdle disease (52).

Typically, pathogenesis and pathophysiology of acquired myoadenylate deaminase deficiency are characteristic of the associated neuromuscular disorder; however, synergistic effects have been noted in patients with a coincidental inherited deficiency and a second inherited metabolic disorder.

Inherited myoadenylate deaminase deficiency is transmitted as an autosomal recessive trait. However, the existence of symptomatic and asymptomatic cases demonstrates variable penetrance of the exertional myalgia associated with this genetic disorder. The AMPD1 gene, which produces transcripts encoding myoadenylate deaminase, is composed of 16 exons and is located on the short arm of chromosome 1 in the region p21-p23 (58). Exon 2, a miniexon composed of only 12 nucleotide base pairs, is subject to an alternative splicing event that removes it from 0.6% to 2% of mature AMPD1 transcripts (38). The identified common mutant AMPD1 allele contains C->T transitions at nucleotides +34 (codon 12 in exon 2) and +143 (codon 48 in exon 3) (37). The latter transition is reported to be functionally silent, whereas the former results in a nonsense codon near the 5'-end of the myoadenylate deaminase open reading frame. Therefore, the mRNA produced from the mutant AMPD1 allele would be predicted to encode a severely truncated myoadenylate deaminase polypeptide. Due to its location in exon 2, the functionally significant transition at nucleotide +34 would be removed from 0.6% to 2% of mature AMPD1 transcripts. Rare mutant alleles have been identified as compound heterozygous genotypes with the common nonsense mutation (23; 65). Whether homozygous or compound heterozygous for the common mutant AMPD1 allele, individuals with an inherited deficiency would be predicted to produce small amounts of catalytically active myoadenylate deaminase owing to alternative splicing of exon 2.

Other isoenzymes of AMP deaminase are present in all human tissues and cells, including skeletal muscle (46; 70). Isoforms L and E are encoded by transcripts produced from the AMPD2 and AMPD3 genes, respectively (32; 33). Isoform E accounts for most of the residual AMP deaminase activity present in muscle extracts from individuals with inherited myoadenylate deaminase deficiency (20). Furthermore, across all tissues and cell types examined, AMPD3 mRNAs are most abundant in skeletal muscle where their production appears regulated by protein/E-box interactions (32). Immunocytochemical analysis has demonstrated differential expression of AMP deaminase isoenzymes in fiber types: myoadenylate deaminase, or isoform M, is expressed predominantly in Type II fibers, and isoform E in Type I fibers (70).

The functional significance of alternative AMPD1 transcript and multiple AMP deaminase isoenzyme expression in skeletal muscle is unknown but does offer testable hypotheses to explain symptomatic and asymptomatic forms of inherited myoadenylate deaminase deficiency. These include variable expression of AMPD1 exon 2- (38) and AMPD3 (57; 43) transcripts. Partial defects in other energy-generating pathways may also contribute to the clinical variability of inherited myoadenylate deaminase deficiency.

Acquired myoadenylate deaminase deficiency also has a genetic component (14) involving a mutant AMPD1 allele in the heterozygous state. In these individuals, inherently able to produce only half of the normal amount of myoadenylate deaminase, other unrelated neuromuscular diseases lower AMP deaminase activity into the deficient range. This profile has been documented in two unrelated cases of myotonic dystrophy and a single case of Sjögren syndrome (54), described in an acquired myoadenylate deaminase deficiency secondary to Type II muscle fiber atrophy (34), and referred to in a number of other cases of severe neuromuscular disease (15). The high prevalence of the mutant AMPD1 allele in numerous sample populations supports this hypothesis, as does the inverse correlation between the relative degree of pathology in several neuromuscular disease states and AMP deaminase activity or AMPD1 transcript abundance (28; 40; 59). However, other cases of acquired myoadenylate deaminase deficiency, initially classified on the basis of clinical presentation, are likely to be homozygous for the mutant allele (ie, a coincidental inherited deficiency). This profile has been reported in 10 patients with acquired myoadenylate deficiency (71). Furthermore, five patients with combined McArdle disease and myoadenylate deaminase deficiency were found to be homozygous for mutant alleles in both the myophosphorylase and AMPD1 genes (69; 49; 50; 35), and a sixth individual was identified with combined inherited defects in muscle phosphofructokinase and AMP deaminase (03).

The myoadenylate deaminase enzyme exhibits a mutually dependent stability relationship with skeletal muscle histidine-proline-rich-glycoprotein (HPRG). Although the clinical significance of this association is unknown, HPRG levels are dramatically reduced in the inherited forms of myoadenylate deaminase deficiency (54).

In addition to its role as an underlying genetic defect associated with metabolic myopathy, the mutant AMPD1 allele has also been extensively examined in patients with cardiovascular diseases. A meta-analysis of eight studies meeting rigorous inclusion and exclusion criteria indicated that the T allele of AMPD1 gene C34T polymorphism correlated with elevated left ventricular ejection fraction (LVEF), reduced left ventricular dilation (LVEDD) and decreased systolic blood pressure, which play protective roles in cardiovascular disease patients, but had no effects on total survival rate and cardiac survival rate for heart failure (11). Furthermore, decreased pulse wave velocity and lower levels of serum ICAM-1a in subjects harboring one or more mutant AMPD1 allele in a high-risk population of coronary artery disease subjects suggest positive effects on aortic stiffness and inflammatory status (67). Additionally, reduced frequency of obesity in coronary artery disease, and reduced hyperglycemia and diabetes in coronary artery disease and heart failure, has been positively associated with the mutant AMPD1 allele (61). Furthermore, accumulating evidence on the association between gene polymorphisms and methotrexate treatment in rheumatoid arthritis predicts a positive response in affected individuals harboring the C->T transition at nucleotide +34 in the AMPD1 gene (06). Moreover, a clinical pharmacogenetics model for predicting response to methotrexate that includes four clinical variables and four SNPs (one of which is the C-> T transition at nucleotide +34 in the AMPD1 gene) shows a good benefit-cost relationship for informing methotrexate (MTX) prescription (30). Conversely, this gene polymorphism has been associated with adverse gastrointestinal effects in juvenile idiopathic arthritis (01).

Epidemiology

Myoadenylate deaminase deficiency is noted histochemically in approximately 2% of muscle biopsies submitted for evaluation, making it the most common of the known enzymopathies of muscle. More than 200 cases have been reported in the literature, approximately half of which present with exertional myalgia (ie, inherited myoadenylate deaminase deficiency) (55). The remainder are secondary to other neuromuscular diseases and would be classified either as acquired or coincidental inherited myoadenylate deaminase deficiency. The identification of a common mutant AMPD1 allele led to a preliminary estimation of its frequency in various populations (37). Using a relatively simple polymerase chain reaction-based diagnostic test, mutant allele frequencies of 12% and 19% were found initially in 59 Caucasians and 13 African Americans, respectively; all of the 106 Japanese subjects surveyed were homozygous for the normal allele. Mutant allele frequencies of 11% to 14% were subsequently found in larger population samples of Caucasians (22; 41; 47), whereas a much lower prevalence (0.5%) was observed in 273 African Americans (47) and in a cohort of greater than 200 suspected myopathic individuals from the Indian subcontinent (05). The relatively high mutant allele frequency in the Caucasian population is sufficient to account for the reported 2% incidence of myoadenylate deaminase deficiency in muscle biopsies. Clearly, 2% of all Caucasians do not have symptoms severe enough to require medical attention; however, these data identify individuals who may be at risk of developing exertional myalgia. Notably, significantly different mutant allele frequencies have been found in the following sample population studies: higher in 320 German myopathic patients compared to a group of 290 subjects without muscle symptoms (22). In addition, a 2006 study identified asymptomatic, inherited myoadenylate deaminase deficiency as a genetic risk factor in individuals who develop pain, weakness, and other symptoms of muscle dysfunction while on lipid-lowering (statin) drug therapy (73).

Research starting in the late 1990s has investigated DNA polymorphisms associated with sports-related characteristics, culminating to date with meta-analyses that indicate that the normal C allele of the AMPD1 gene C34T polymorphism is related to enhanced athletic performance. For example, among 41 of the 114 reported genetic markers associated with elite athlete status, the C allele of the AMPD1 gene C34T polymorphism is positively associated with endurance and power (62). A second meta-analysis evaluated the relationship between four genetic markers reportedly associated with power athlete status, and three of these, including the C allele of the AMPD1 gene C34T polymorphism, are significantly more prevalent in power athletes (27). A third meta-analysis examined DNA polymorphisms associated with athlete status, physical performance, and injury risk in soccer players (39). Among six genetic markers associated with physical performance, the C allele of the AMPD1 gene C34T polymorphism in combination with three other “favorable” genetic markers correlates with greater agility (change of direction). Moreover, the C allele of the AMPD1 gene C34T polymorphism is the only genetic variant to date that appears to influence acceleration and speed in this athletic cohort.

Diagnostic workup

An ischemic forearm protocol that measures exertional increases in plasma ammonia and lactate offers a relatively noninvasive and simple test for diagnosing suspected myoadenylate deaminase deficiency (16). Based on the risk of rhabdomyolysis associated with glycogenosis under ischemic conditions, a nonischemic test was developed, which is now more commonly used with similar diagnostic accuracy (26). In both tests, because AMP deaminase is the major ammonia-producing enzyme in muscle, a flat ammonia profile indicates a deficiency. However, care must be taken to ensure that enough work is performed by the subject in order to prevent a false-negative result. A flat ammonia response accompanied by a rise in plasma lactate of 2.5 to 4 mM (approximately 20 to 35 mg/dL) is sufficient to ensure a reliable diagnosis (14; 07).

Although myoadenylate deaminase deficiency was historically confirmed in muscle biopsy by histochemical stain (18) or by direct enzymatic assay (13), the availability of reliable genetic tests that simply require a blood sample precludes the need for a muscle biopsy to confirm an AMPD1 deficiency. The mutant AMPD1 allele can be readily confirmed by a polymerase chain reaction-based test using genomic DNA isolated from whole blood (37). Nucleotide +34 is at the 3'-boundary of exon 2 in the AMPD1 gene, and a C->T transition at this position destroys a Mae II restriction endonuclease site in the mutant allele. Alternative polymerase chain reaction-based and allele-specific oligomer polymerase chain reaction-based assays are also available for diagnosing the mutant AMPD1 allele (21; 17; 41). Gene panels including AMPD1 have been developed using next-generation sequencing (eg, National Library of Medicine GTR Test ID: GTR000502959.3). Although biochemical and immunological criteria have been described that may be used to distinguish inherited and acquired forms of the disease (14), genetic tests currently provide the most reliable method by which to establish that a myoadenylate deaminase deficiency is inherited. Furthermore, due to the high frequency of the mutant AMPD1 allele in the Caucasian population, many cases of acquired myoadenylate deaminase deficiency are also suspected of harboring this defect on one or both homologues of chromosome 1. Once AMPD1 mutation is established by genetic testing, it is important to also consider other contributing causes, genetic or acquired, in symptomatic individuals.

References

01: Avramovic MZ, Dolžan V, Toplak N, Accetto M, Lusa L, Avčin T. Relationship between polymorphisms in methotrexate pathway genes and outcome of methotrexate treatment in a cohort of 119 patients with juvenile idiopathic arthritis. J Rheumatol 2017;44(8):1216-23. PMID 28572465
02: Bellver J, Cervera J, Boldo A, et al. Myoadenylate deaminase deficiency myopathy in pregnancy. Arch Gynecol Obstet 1997;259(3):157-9. PMID 9187470
03: Bruno C, Minetti C, Shanske S, et al. Combined defects of muscle phosphofructokinase and AMP deaminase in a child with myoglobinuria. Neurology 1998;50(1):296-8. PMID 9443500
04: Bruyland M, Ebinger G. Beneficial effects of a treatment with xylitol in a patient with myoadenylate deaminase deficiency. Clin Neuropharmacol 1994;17:492-3. PMID 9316703
05: Chakravorty S, Nallamilli BRR, Khadilkar SV, et al. Clinical and genomic evaluation of 207 genetic myopathies in the Indian subcontinent. Front Neurol 2020;11:559327. PMID 33250842
06: Chen Y, Zou K, Sun J, Yang Y, Liu G. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics 2017;18(2):175-95. PMID 27992285
07: Coleman RA, Stajich JM, Pact VW, Pericak-Vance MA. The ischemic exercise test in normal adults and in patients with weakness and cramps. Muscle Nerve 1986;9:216-21. PMID 3702911
08: de Ruiter CJ, May AM, van Engelen BG, Wevers RA, Steenbergen-Spanjers GC, de Haan A. Muscle function during repetitive moderate-intensity muscle contractions in myoadenylate deaminase-deficient Dutch subjects. Clin Sci (Lond) 2002;102(5):531-9. PMID 11980572
09: de Ruiter CJ, van Engelen BG, Wevers RA, de Haan A. Muscle function during fatigue in myoadenylate deaminase-deficient Dutch subjects. Clin Sci 2000;98:579-85. PMID 10781389
10: Engel AG, Potter CS, Rosevear JW. Nucleotides and adenosine monophosphate deaminase activity of muscle in primary hypokalaemic periodic paralysis. Nature 1964;202:670-2. PMID 14190030
11: Feng AF, Liu ZH, Zhou SL, Zhao SY, Zhu YX, Wang HX. Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis. BMC Cardiovasc Disord 2017;17(1):174-82. PMID 28673246
12: Fischer H, Esbjornsson M, Sabina RL, Stromberg A, Peyrard-Janvid M, Norman B. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects. J Appl Physiol 2007;103(1):315-22. PMID 17463303
13: Fishbein WN. Enzyme indicator assays. I. Adenylate deaminase: principles and application to human muscle biopsies and blood cells. Biochem Med 1979;22:307-22. PMID 43727
14: Fishbein WN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 1985;33:158-69. PMID 4004819
15: Fishbein WN. Primary, secondary, and coincidental types of myoadenylate deaminase deficiency. Ann Neurol 1999;45:547-8. PMID 10211487
16: Fishbein WN, Armbrustmacher VW, Griffin JL. Myoadenylate deaminase deficiency: a new disease of muscle. Science 1978;200:545-8. PMID 644316
17: Fishbein WN, Davis JI, Foellmer JW, Nieves S, Merezhinskaya N. A competitive allele-specific oligomers polymerase chain reaction assay for the cis double mutation in AMPD1 that is the major cause of myo-adenylate deaminase deficiency. Mol Diagn 1997;2:121-8. PMID 10462599
18: Fishbein WN, Griffin JL, Armbrustmacher VW. Stain for skeletal muscle adenylate deaminase: an effective tetrazolium stain for frozen biopsy specimens. Arch Path Lab Med 1980;104:462-6. PMID 6158302
19: Fishbein WN, Muldoon SM, Deuster PA, Armbrustmacher VW. Myoadenylate deaminase deficiency and malignant hyperthermia susceptibility: is there a relationship. Biochem Med 1985;34:344-54. PMID 4096721
20: Fishbein WN, Sabina RL, Ogasawara N, Holmes EW. Immunologic evidence for three isoforms of AMP deaminase (AMPD) in mature skeletal muscle. Biochim Biophys Acta 1993;1163:97-104. PMID 8476935
21: Gross M. New method for detection of C34-T mutation in the AMPD1 gene causing myoadenylate deaminase deficiency. Ann Rheum Dis 1994;53:353-4. PMID 8017994
22: Gross M. Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. J Inherit Metab Dis 1997;20:186-92. PMID 9211191
23: Gross M, Rotzer E, Kolle P, et al. A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul Disord 2002;12(6):558-65. PMID 12117480
24: Hand BD, Roth SM, Roltsch MH, et al. AMPD1 polymorphism and the vasodilatory response to ischemia. Life Sci 2006;79(15):1413-8. PMID 16707139
25: Hayes DJ, Summers BA, Morgan-Hughes JA. Myoadenylate deaminase deficiency or not. Observations on two brothers with exercise-induced muscle pain. J Neurol Sci 1982;53:125-36. PMID 7057200
26: Hogrel JY, Laforet P, Ben Yaou R, Chevrot M, Eymard B, Lombes A. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001;26:1733-8. PMID 11425942
27: Ipekoglu G, Cetin T, Apaydin N, Calcali T, Senel E. The role of AGT, AMPD1, HIF1alpha, IL-6 gene polymorphisms in the athlete’s power status: a meta-analysis. J Human Kinet 2023;89:77-87. PMID 38053960
28: Kar NC, Pearson CM. Muscle adenylic acid deaminase activity: selective decrease in early-onset Duchenne muscular dystrophy. Neurology 1973;23:478-82. PMID 4735464
29: Lecky BR. Failure of D-ribose in myoadenylate deaminase deficiency. Lancet 1983;1:193. PMID 6130241
30: Lopez-Rodriguez R, Ferreiro-Iglesias A, Lima A, et al. Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics J 2018;18(4):539-45. PMID 29520081
31: Lowenstein JM. Ammonia production in muscle and other tissues: The purine nucleotide cycle. Physiol Rev 1972;52:382-414. PMID 4260884
32: Mahnke-Zizelman DK, Eddy R, Shows TB, Sabina RL. Characterization of the human AMPD3 gene reveals that 5' exon usage is subject to transcriptional control by three tandem promoters and alternative splicing. Biochem Biophys Acta 1996a;1306:75-92. PMID 8611627
33: Mahnke-Zizelman DK, van den Bergh F, Bausch-Jurken MT, et al. Cloning, sequence and characterization of the human AMPD2 gene: evidence for transcriptional regulation by two closely spaced promoters. Biochem Biophys Acta 1996b;1308(2):122-32. PMID 8764830
34: Marin R, Connick E. Tension myalgia versus myoadenylate deaminase deficiency: a case report. Arch Phys Med Rehabil 1997;78:95-7. PMID 9014967
35: Martinuzzi A, Sartori E, Fanin M, et al. Phenotype modulators in myophosphorylase deficiency. Ann Neurol 2003;53(4):497-502. PMID 12666117
36: Mercelis R, Martin JJ, de Barsy T, Van den Berghe G. Myoadenylate deaminase deficiency: absence of correlation with exercise intolerance in 452 muscle biopsies. J Neurol 1987;234:385-9. PMID 3655841
37: Morisaki T, Gross M, Morisaki H, Pongratz D, Zollner N, Holmes EW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 1992;89:6457-61. PMID 1631143
38: Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993;91:2275-80. PMID 8486786
39: Murtaugh CF, Hall ECR, Brownlee TE, Drust B, Williams AG, Erskine RM. The genetic association with athlete status, physical performance, and injury risk in soccer. Int J Sports Med 2023;44:941-60. PMID 37253386
40: Nagao H, Habara S, Morimoto T, et al. AMP deaminase activity of skeletal muscle in neuromuscular disorders in childhood: Histochemical and biochemical studies. Neuropediatrics 1986;17(4):193-8. PMID 3808228
41: Norman B, Mahnke-Zizelman DK, Vallis A, Sabina RL. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol 1998;85:1273-8. PMID 9760316
42: Norman B, Nygren AT, Nowak J, Sabina RL. The effect of AMPD1 genotype on blood flow response to sprint exercise. Eur J Appl Physiol 2008;103(2):173-80. PMID 18224333
43: Norman B, Sabina RL. Myoadenylate deaminase deficiency. In: Valle D, Beaudet AL, Vogelstein B, et al, editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2010: Chapter 110 (update).
44: Norman B, Sabina RL, Jansson E. Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol 2001;91:258-64. PMID 11408438
45: Noury JB, Zagnoli F, Petit F, Marcorelles P, Rannou F. Exercise efficiency impairment in metabolic myopathies. Sci Rep 2020;10(1):8765-73. PMID 32472082
46: Ogasawara N, Goto H, Yamada Y, Watanabe T, Asano T. AMP deaminase isozymes in human tissues. Biochim Biophys Acta 1982;714:298-306. PMID 7034783
47: Rico-Sanz J, Rankinen T, Joanisse DR, et al. Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family study. Physiol Genomics 2003;14(2):161-6. PMID 12783984
48: Riksen NP, Franke B, Oyen WJ, et al. Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. Eur Heart J 2007;28(9):1085-91. PMID 17376785
49: Rubio JC, Martin MA, Bautista J, Campos Y, Segura D, Arenas J. Association of genetically proven deficiencies of myophosphorylase and AMP deaminase: a second case of “double trouble.” Neuromuscul Disord 1997;7:387-9. PMID 9327403
50: Rubio JC, Martin MA, del Hoyo P, et al. Molecular analysis of Spanish patients with AMP deaminase deficiency. Muscle Nerve 2000;23(8):1175-8. PMID 10918252
51: Rubio JC, Martin MA, Rabadan M, et al. Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance. J Appl Physiol 2005;98(6):2108-12. PMID 15677729
52: Rubio JC, Perez M, Mate-Munoz JL, et al. AMPD1 genotypes and exercise capacity in McArdle patients. Int J Sports Med 2008;29(4):331-5. PMID 17687759
53: Saab R, Zouk AN, Mastouri R, Skaar TC, Philips S, Kreutz RP. AMPD1 polymorphism and response to regadenoson. Pharmacogenomics 2015;16(16):1807-15. PMID 26554440
54: Sabbatini AR, Toscano A, Aguennouz M, et al. Immunohistochemical analysis of human skeletal muscle AMP deaminase deficiency. Evidence of a correlation between the muscle HPRG content and the level of the residual AMP deaminase activity. J Muscle Res Cell Motil 2006;27(1):83-92. PMID 16570231
55: Sabina RL. Myoadenylate deaminase deficiency. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Kunkel LM, editors. The Molecular and Genetic Basis of Neurological Disease. Boston: Butterworth-Heinemann, 1993:261-75.
56: Sabina RL, Fishbein WN, Pezeshkpour G, Clarke PR, Holmes EW. Molecular analysis of the myoadenylate deaminase deficiencies. Neurology 1992;42:170-9. PMID 1370861
57: Sabina RL, Holmes EW. Myoadenylate deaminase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th edition. New York: McGraw-Hill, 2001:2627-38.
58: Sabina RL, Morisaki T, Clarke P, et al. Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem 1990;265(16):9423-33. PMID 2345176
59: Sabina RL, Sulaiman AR, Wortmann RL. Molecular analysis of acquired myoadenylate deaminase deficiency in polymyositis (idiopathic inflammatory myopathy). Adv Exp Med Biol 1991;309B:203-5. PMID 1781368
60: Sabina RL, Swain JL, Olanow CW, et al. Myoadenylate deaminase deficiency: functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 1984;73(3):720-30. PMID 6707201
61: Safranow K, Suchy J, Jakubowska K, et al. AMPD1 gene mutations are associated with obesity and diabetes in Polish patients with cardiovascular diseases. J Appl Genet 2011;52(1):67-76. PMID 21108053
62: Semenova EA, Hall ECR, Ahmetov II. Genes and athletic performance: the 2023 update. Genes (Basel) 2023;14(6):1235-66. PMID 37372415
63: Shumate J, Katnik R, Ruiz M, et al. Myoadenylate deaminase deficiency. Muscle Nerve 1979;2(3):213-6. PMID 503106
64: Sinkeler SP, Binkhorst RA, Joosten EM, Wevers RA, Coerwinkel MM, Oei TL. AMP deaminase deficiency: study of the human skeletal muscle purine metabolism during ischaemic isometric exercise. Clin Sci 1987;72:475-82. PMID 3829596
65: Teijeira S, San Millan B, Fernandez JM, et al. Myoadenylate deaminase deficiency: clinico-pathological and molecular study of a series of 27 Spanish cases. Clin Neuropathol 2009;28(2):136-42. PMID 19353846
66: Thomaes T, Thomis M, Onkelinx S, et al. A genetic predisposition score for muscular endophenotypes predicts the increase in aerobic power after training: the CAREGENE study. BMC Genet 2011;12:84. PMID 21967077
67: Tousoulis D, Kioufis S, Siasos G, et al. The impact of AMPD1 gene polymorphism on vascular function and inflammation in patients with coronary artery disease. Int J Cardiol 2014;172:e516-e8. PMID 24508110
68: Toyama K, Morisaki H, Kitamura Y, et al. Haplotype analysis of human AMPD1 gene: origin of common mutant allele. J Med Genet 2004;41(6):e74. PMID 15173240
69: Tsujino S, Shanske S, Carroll JE, Sabina RL, DiMauro S. Double trouble: combined myophosphorylase and AMP deaminase deficiency in a child homozygous for nonsense mutations at both loci. Neuromuscul Disord 1995;5:263-6. PMID 7580237
70: van Kuppevelt TH, Veerkamp JH, Fishbein WN, Ogasawara N, Sabina RL. Immunolocalization of AMP-deaminase isozymes in human skeletal muscle and cultured muscle cells: concentration of isoform M at the neuromuscular junction. J Histochem Cytochem 1994;42:861-8. PMID 8014469
71: Verzijl HT, van Engelen BG, Luyten JA, et al. Genetic characteristics of myoadenylate deaminase deficiency. Ann Neurol 1998;44(1):140-3. PMID 9667605
72: Vladutiu GD. Complex phenotypes in metabolic muscle diseases. Muscle Nerve 2000;23:1157-9. PMID 10918250
73: Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34(2):153-62. PMID 16671104
74: Vockley J, Rinaldo P, Bennett MJ, Matern D, Vladutiu GD. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol Gen Metab 2000;71(1-2):10-8. PMID 11001791
75: Zollner N, Reiter S, Gross M, et al. Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose. Klin Wochenschr 1986;64(24):1281-90. PMID 3102830

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Richard L Sabina PhD

Dr. Sabina of Oakland University William Beaumont School of Medicine has no relevant financial relationships to disclose.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Emma Ciafaloni MD FAAN
Michael K Hehir MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor

autosomal recessive
Population groups selectively affected: Caucasians

African Americans
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Other disorders of purine and pyrimidine metabolism: 277.2

Myalgia and myositis unspecified: 729.1
ICD-10: Other disorders of purine and pyrimidine metabolism: E79.8

Myalgia: M79.1
OMIM: Adenosine monophosphate deaminase 1: *102770

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Myoadenylate deaminase deficiency

Associated Disorders

Acid maltase deficiency
Adult-onset spinal muscular atrophy
Amyotrophic lateral sclerosis
Axonal neuropathy
Becker muscular dystrophy
- Cardiomyopathy and type I fiber atrophy
- Carnitine palmitoyltransferase deficiency
- Denervation atrophy
- Dermatomyositis
- Facioscapulohumeral dystrophy
- Focal motor neuron loss
- Hyperornithinemia
- Hyperuricemia
- Hypokalemic periodic paralysis
- Hypotonia
- Inflammatory myopathy
- Kugelberg-Welander syndrome
- Malignant hyperthermia
- McArdle disease
- Muscle-eye-brain disease
- Myasthenia gravis
- Myotonic dystrophy
- Peripheral neuropathy
- Polyarteritis
- Polymyositis
- Polyneuropathy
- Progressive systemic sclerosis
- Sarcoidosis
- Trichinosis
- Type II fiber atrophy
- Werdnig-Hoffmann disease

Differential Diagnosis

exertional myalgia without myoadenylate deaminase deficiency
advanced-stage neuromuscular disease without myoadenylate deaminase deficiency

Also Relevant

Duchenne muscular dystrophy
Myoglobinuria
Periodic paralysis and related disorders

Clinical Categories

Neuromuscular Disorders

Web References

Testing

Adenosine Monophosphate Deaminase 1

Myoadenylate deaminase deficiency …

Myoadenylate deaminase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Genotype–drug interaction

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

Periodic paralysis and the nondystrophic myotonias (skeletal muscle channelopathies)

Myoadenylate deaminase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Genotype–drug interaction

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

Periodic paralysis and the nondystrophic myotonias (skeletal muscle channelopathies)

This is an article preview.
Start a Free Account
to access the full version.